Innovent hands Lilly another win over Novo Nordisk

China-headquartered Innovent Bio (1801.HK) has announced that the fourth Phase III trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint.

The results showed that, in Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide showed superior efficacy to Novo Nordisk’s (NOV: N) GLP-1 receptor agonist, Ozempic (semaglutide) on the primary endpoint—the proportion of participants achieving glycated hemoglobin (HbA1c) of more than 7% and at least 10% body weight reduction from baseline at week 32.

At the same point, the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group, respectively, and the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6% in the semaglutide group, respectively.